Nephrologists, Critical Care and Emergency Physicians Express an Extremely High Unmet Need in the Area of Acute Kidney Inj

EXTON, Penn.--(BUSINESS WIRE)-- Relative to a number of other conditions in nephrology, acute kidney injury (AKI), previously termed acute renal failure, is considered to be one of the areas of greatest need, according to a recent report from BioTrends. The lack of currently available treatments, the high incidence and the high morality rates are key factors influencing the high perceived need.

There are a number of developments, either recent or on the horizon, that are expected to positively impact the field, including the development of biomarkers to earlier diagnose the condition, the availability of staging systems to better classify patients, as well as a number of treatments being studied to prevent or treat AKI. There remains much controversy, however, as to the benefit of biomarkers and staging in clinical practice, outside of the research setting. Additionally, the appropriate focus of future development efforts for therapeutics for AKI (e.g. prevention versus treatment, sepsis versus cardiac surgery versus contrast nephropathy, etc.) is also an area of debate in the field. However, key opinion leaders tend to mention and express excitement about products in development from a number of companies including Allocure, Quark, and Thrasos.

TreatmentTrends®: Acute Kidney Injury is a syndicated annual report series, based on primary market research that provides a comprehensive view of the current and expected future management of AKI. The 2011 survey was fielded with 101 nephrologists, 50 critical care, and 50 emergency room physicians. Qualitative interviews were also conducted with ten key opinion leaders in AKI. In addition to providing insight into management strategies, the report details challenges, controversies, greatest perceived needs, and development efforts in the field.

As a follow up to the TreatmentTrends report, BioTrends and its sister company, Arlington Medical Resources, will collaborate to offer a new syndicated offering - ChartTrends®: Acute Kidney Injury. This report, which is accompanied by a database of over 1,000 patient records of patients recently diagnosed with AKI, will offer a comprehensive view into the patient characteristics, treatment interventions and outcomes of patients with AKI. ChartTrends provide details around disease management, patient demographics, co-morbid conditions, laboratory results, and factors causing acute kidney injury.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Sharon Funk, 404-223-2963
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Oncology  Other Health  Automotive  General Automotive

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.